A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2018
At a glance
- Drugs NEO-PV 01 (Primary) ; Cyclophosphamide; Poly ICLC
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 09 Feb 2018 Planned initiation date changed from 30 Sep 2017 to 1 Sep 2018.
- 20 Jul 2017 New trial record